Tretten Or Novothirteen Market Report 2026

Tretten Or Novothirteen Market Overview

• The Tretten Or Novothirteen market growth in the historic period has been driven by increased diagnosis of factor xiii deficiency, advancements in recombinant protein production • Market expansion is supported by expansion of precision medicine adoption, rising investments in orphan drug development • Growth Driver: Growing Awareness Of Rare Bleeding Disorders Driving Market Growth Due To Heightening Demand For Targeted Hemophilia Therapies • North America was the largest region in 2025.

What Is Covered Under Tretten Or Novothirteen Market?

Tretten (Novothirteen) is a recombinant therapy used to treat factor XIII deficiency, a rare bleeding disorder. Its mechanism of action involves the provision of recombinant factor XIII, which stabilizes blood clots by cross-linking fibrin strands. Tretten is typically administered by intravenous infusion and is used as part of a treatment regimen for patients with PNH or aHUS to help reduce the risk of complications such as organ damage or blood clots. The main types of indications for tretten or novothirteen are hemophilia B and surgical prophylaxis. Hemophilia B is a genetic bleeding disorder caused by a deficiency in clotting factor IX, leading to impaired blood clotting and prolonged bleeding. It is available in various formulations, such as lyophilized powder and intravenous solution. It is distributed through various channels such as hospital and clinics, retail and specialty pharmacies and is used by various end users including adult patient and pediatric patients.

What Is The Tretten Or Novothirteen Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of precision medicine adoption, rising investments in orphan drug development, increasing demand for safer long-term clot stabilization therapies, advancements in recombinant biologics manufacturing, growing focus on home-based infusion therapies. Major trends in the forecast period include increasing adoption of recombinant coagulation therapies, rising focus on rare bleeding disorder treatments, growing emphasis on targeted protein replacement therapies, expansion of personalized treatment regimens, enhanced manufacturing quality and purity standards.

Global Tretten Or Novothirteen Market Segmentation

1) By Clinical Indication: Hemophilia B, Surgical Prophylaxis 2) By Formulation: Lyophilized Powder, Intravenous Solution 3) By Distribution Channel: Hospital And Clinics, Retail And Specialty Pharmacies 4) By End User: Adult Patient, Pediatric Patients

What Are The Drivers Of The Tretten Or Novothirteen Market?

The increasing awareness of rare bleeding disorders is expected to propel the growth of the tretten or novothirteen market going forward. Rare bleeding disorders are uncommon conditions impair the blood's ability to clot adequately such as hemophilia, von willebrand disease, and factor XIII deficiency. The rise in awareness of rare bleeding disorders is due to improved diagnostic capabilities, patient advocacy efforts, and educational campaigns, leading to earlier detection, better treatment access, and improved patient outcomes. Tretten (also known as NovoThirteen) aids in treating rare bleeding disorders by providing a recombinant form of activated Factor XIII, essential for blood clot stabilization, thus reducing the risk of bleeding in patients with Factor XIII deficiency. For instance, in March 2024, according to the National Institute for Health and Care Excellence, a UK-based non-departmental public body, in 2022-2023, there were 2,069 individuals in the UK diagnosed with hemophilia B, including 374 with severe disease and 351 with moderate disease. Therefore, increasing awareness of rare bleeding disorders drives growth in the tretten or novothirteen industry. The growing healthcare expenditure is expected to propel the growth of the tretten or novothirteen market going forward. Healthcare expenditure is the total amount of financial resources spent on healthcare services by governments, businesses, and individuals, including medical treatments, hospital care, medications, and public health initiatives. The increase in healthcare expenditure is due to advancements in medical technology, increasing healthcare needs, and an increasing emphasis on quality patient care, leading to higher investments globally. With growing healthcare expenditure, more funds are allocated to research, development, and accessibility of treatments for rare and complex conditions like congenital factor XIII deficiency, which tretten is designed to treat. For instance, in June 2025, according to the Centers for Medicare and Medicaid Services, a US-based federal agency, in 2023, Medicare spending grew 8.1% to $1,029.8 billion or 21% of total national health expenditure, Medicaid spending grew 7.9% to $871.7 billion or 18 percent of total national health expenditure, and private health insurance spending grew 11.5% to $1,464.6 billion or 30% of total national health expenditure. Therefore, growing healthcare expenditure drives growth in the tretten or novothirteen industry. The rising demand for personalized medicine is expected to propel the growth of the tretten or novothirteen market going forward. Personalized medicine refers to an approach in healthcare that customizes treatment plans for individual patients by considering their genetic information, lifestyle, and environmental factors to improve the effectiveness of care. The rising demand for personalized medicine is attributed to genomics and diagnostic technologies advancements, enabling more tailored and effective treatments. Tretten or Novothirteen acts as a personalized medicine by providing targeted treatment for individuals with hemophilia B, tailored to their specific clotting factor deficiencies, thereby improving bleeding control and reducing the risk of bleeding episodes. For instance, in February 2024, Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the Food and Drug Administration approved 16 new personalized treatments for rare disease patients, a significant increase from the six approved in 2022. Among these new approvals, seven are cancer drugs, and three target other diseases and conditions. Therefore, the rising demand for personalized medicine drives growth in the tretten or novothirteen industry.

Key Players In The Global Tretten Or Novothirteen Market

Major companies operating in the tretten or novothirteen market are Novo Nordisk A/S

Regional Insights

North America was the largest region in the tretten or novothirteen market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Tretten Or Novothirteen Market?

The tretten or novothirteen market consists of sales of plasma-derived factor XIII concentrates, diagnostic kits, assays, and ancillary products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tretten Or Novothirteen Market Report 2026?

The tretten or novothirteen market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tretten or novothirteen industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.